YEATS Domain Inhibitors Transform Acute Leukemia Therapy
The First Class of Inhibitors for YEATS Domain as Potential Therapeutic Agents for Acute Leukemia
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This innovation introduces the first small-molecule inhibitors targeting the ENL YEATS domain, a novel therapeutic target in mixed lineage leukemia (MLL). These inhibitors selectively disrupt ENL-chromatin interaction and inhibit oncogene transcription, effectively targeting MLL rearranged acute leukemia. Applications include anti-leukemia drugs that address a significant unmet need in aggressive blood cancers with poor prognosis. In vitro studies confirm the inhibitors' biological activity and selective engagement with MLL cell lines. The technology holds a provisional US patent, providing a strong foundation for further development.
IP Type or Form Factor: Patent Pending; Process & Method; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Pharmaceutical Engineering; Biotechnology
